Evidence map›Paper›PMID 35741010›Full record

ReviewCells2022

MicroRNA Networks in Cognition and Dementia.

Grace S Blount, Layton Coursey, Jannet Kocerha

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 28 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. A Perspective: Challenges in Dementia Research.Medicina (Kaunas, Lithuania) · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Grace S BlountDepartment of Chemistry, Georgia Southern University, Statesboro, GA 30460, USA.
Layton CourseyDepartment of Chemistry, Georgia Southern University, Statesboro, GA 30460, USA.
Jannet KocerhaDepartment of Chemistry, Georgia Southern University, Statesboro, GA 30460, USA.
Georgia Southern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The change from viewing noncoding RNA as "junk" in the genome to seeing it as a critical epigenetic regulator in almost every human condition or disease has forced a paradigm shift in biomedical and clinical research. Small and long noncoding RNA transcripts are now routinely evaluated as putative diagnostic or therapeutic agents. A prominent role for noncoding microRNAs in the central nervous system has uncovered promising new clinical candidates for dementia-related disorders, treatments for which currently remain elusive even as the percentage of diagnosed patients increases significantly. Cognitive decline is a core neurodegenerative process in Alzheimer's Disease, Frontotemporal Dementia, Lewy body dementia, vascular dementia, Huntington's Disease, Creutzfeldt-Jakob disease, and a significant portion of Parkinson's Disease patients. This review will discuss the microRNA-associated networks which influence these pathologies, including inflammatory and viral-mediated pathways (such as the novel

Indexed as

CognitionDementiaMicroRNAsCOVID-19HumansMicroRNAsAlzheimer’sbiomarkersCOVID-19dementiaFTDmiRNAnoncodingtherapeuticsvascular

Identifiers

PMID35741010
PMCPMC9221254
OpenAlexW4281853415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.